Clinical Trial: Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia

This study is no longer recruiting patients.

Sponsors and Collaborators: National Cancer Institute (NCI)
University of Michigan Comprehensive Cancer Center
Information provided by: National Cancer Institute (NCI)


RATIONALE: Tretinoin may help cervical neoplasia cells develop into normal cervical cells. It is not yet known whether tretinoin is more effective than a placebo in preventing cervical cancer in patients with cervical neoplasia. PURPOSE: Randomized clinical trial to study the effectiveness of tretinoin in preventing cervical neoplasia from developing into cervical cancer.

Condition Treatment or Intervention
Cervical Cancer
 Drug: chemoprevention of cancer
 Procedure: cancer prevention intervention
 Drug: tretinoin

MedlinePlus related topics:  Cervical Cancer

Study Type: Interventional
Study Design: Prevention

Official Title: Randomized Study of Tretinoin and Intermediate Biomarkers in Patients With Cervical Intraepithelial Neoplasia II or III

Further Study Details: 

Study start: January 1999

OBJECTIVES: I. Determine whether topical tretinoin reduces the number of viral genome copies of human papilloma virus (HPV) per cell and inhibits HPV E6/E7 gene expression in patients with cervical dysplasia. II. Determine the dose of tretinoin for use in a definitive trial that produces the best overall modulation of these biomarkers.

PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are stratified according to cervical intraepithelial neoplasia classification (II vs III). Patients are randomized to 1 of 4 arms. Arm I: Patients receive low-dose tretinoin topically via cervical cap and polyurethane ether foam sponge changed daily for 4 days. Arm II: Patients receive intermediate-dose tretinoin as in arm I. Arm III: Patients receive high-dose tretinoin as in arm I. Arm IV: Patients receive placebo topically as in arm I therapy. Patients are followed for 6 months.

PROJECTED ACCRUAL: A total of 180 patients (45 per arm) will be accrued for this study.


Ages Eligible for Study:  14 Years and above



--Disease Characteristics--

--Prior/Concurrent Therapy--

  • Biologic therapy: Not specified
  • Chemotherapy: At least 1 week since prior tretinoin; No prior retinoids (greater than 25,000 IU vitamin A or equivalent for at least 3 months); No other tretinoin during or for 3 months after study
  • Endocrine therapy: No concurrent regular steroids
  • Radiotherapy: Not specified
  • Surgery: See Disease Characteristics
  • Other: No concurrent regular anticoagulant medication; No concurrent nutritional supplements other than 2 multivitamins per day

--Patient Characteristics--

  • Age: Over 14
  • Performance status: Karnofsky 80-100%
  • Life expectancy: Not specified
  • Hematopoietic: Not specified
  • Hepatic: Not specified
  • Renal: Not specified
  • Immunologic: No proliferative skin disorder (e.g., psoriasis); No diagnosed autoimmune disorders; No allergy to tretinoin or latex
  • Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception (except intrauterine device) during and for 3 months after study; Normal diet with adequate protein and carbohydrate intake; No in-utero exposure to diethylstilbesterol; No prior malignancy; No prior toxic shock syndrome

Location Information

      University of Michigan Comprehensive Cancer Center, Ann Arbor,  Michigan,  48109-0752,  United States

Study chairs or principal investigators

Mack T. Ruffin, IV,  Study Chair,  University of Michigan Comprehensive Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000066670; CCUM-9609; NCI-P98-0131
Record last reviewed:  December 2003
Last Updated:  October 13, 2004
Record first received:  November 1, 1999 Identifier:  NCT00003598
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005